secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-06-01T10:30:22+00:00
Accession:  0001193125-26-249594
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates pipeline: VMT-α-NET durable disease control; VMT01 and PSV359 progress
--------------------------------------------------------------------------------

- VMT-α-NET (SSTR2+ NET) Phase 1/2a shows durable disease control; potential registration study at current dose level.
- VMT01 (MC1R melanoma) Phase 1/2a: preliminary anti-tumor activity observed at 3.0 mCi dose.
- PSV359 (FAP-ɑ solid tumors) Phase 1/2a demonstrates improved tumor retention in ongoing trial.
- Integrated isotope production enables direct-to-hospital delivery and regional manufacturing for supply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526249594/0001193125-26-249594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526249594/catx-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-249594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer